APL can be diagnosed in patients with abnormal hematopoiesis and characteristic cytogenetic abnormalities with t(15;17), regardless of the percentage of marrow blasts.9PML‐RARα FG transcript level can reflect the abnormal leukemia blasts load, quantitatively document disease burden, and confirm molecular remission.10 The goal of consolidation therapy for APL is a durable molecular remission, defined as undetectable PML‐RARα FG.7, 11 Rigorous sequential MRD monitoring by RT‐qPCR coupled with pre‐emptive therapy can help reduce clinical relapse rates in APL patients.5, 8. The gene discussed is PML; the disease is acute promyelocytic leukemia.